Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers-Reference-Cited by-同舟云学术

Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers

Published:2002-03 Issue:3 Volume:87 Page:1239-1246
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:The Journal of Clinical Endocrinology & Metabolism

Author:

Nauck Michael A.,Heimesaat Markus M.,Behle Kai,Holst Jens J.,Nauck Markus S.,Ritzel Robert,Hüfner Michael,Schmiegel Wolff H.

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Cited by 363 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incretin therapy in feline diabetes mellitus – A review of the current state of research;Domestic Animal Endocrinology;2024-10

2. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review;Cureus;2024-09-01

3. Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs;Journal of Clinical Medicine;2024-08-09

4. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists;Frontiers in Endocrinology;2024-07-24

5. Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity;Expert Opinion on Investigational Drugs;2024-07-17